HYPERPHOSPHATEMIA PATIENTS ON HEMODIALYSIS
Clinical trials for HYPERPHOSPHATEMIA PATIENTS ON HEMODIALYSIS explained in plain language.
Never miss a new study
Get alerted when new HYPERPHOSPHATEMIA PATIENTS ON HEMODIALYSIS trials appear
Sign up with your email to follow new studies for HYPERPHOSPHATEMIA PATIENTS ON HEMODIALYSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for dialysis patients: TS-172 targets dangerous phosphate buildup
Disease control Recruiting nowThis study tests a new medicine called TS-172 in 30 adults with high phosphate levels who are on hemodialysis (kidney machine) three times a week. The goal is to see if TS-172 can help bring phosphate levels down to a safer target. Participants will take the drug alongside their …
Matched conditions: HYPERPHOSPHATEMIA PATIENTS ON HEMODIALYSIS
Phase: PHASE3 • Sponsor: Taisho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 11:41 UTC
-
New drug aims to control phosphate in dialysis patients
Disease control Recruiting nowThis study tests a new medicine called TS-172 for people on dialysis who have high phosphate levels. It will check if the drug is safe and works well over a long time. About 300 adults who already take phosphate binders will join.
Matched conditions: HYPERPHOSPHATEMIA PATIENTS ON HEMODIALYSIS
Phase: PHASE3 • Sponsor: Taisho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 11:36 UTC
-
New hope for dialysis patients: experimental drug targets dangerous phosphorus levels
Disease control Recruiting nowThis study tests an experimental drug called TS-172 in 100 adults on hemodialysis who have high phosphorus levels (hyperphosphatemia). Participants continue their usual phosphate binders and are randomly assigned to receive TS-172 or a placebo. The main goal is to see if TS-172 h…
Matched conditions: HYPERPHOSPHATEMIA PATIENTS ON HEMODIALYSIS
Phase: PHASE3 • Sponsor: Taisho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 20, 2026 11:54 UTC